Andy Hsieh
Stock Analyst at William Blair
(4.44)
# 1,085
Out of 4,491 analysts
330
Total ratings
48.5%
Success rate
11.7%
Average return
Main Sectors:
Stocks Rated by Andy Hsieh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KLRA Kailera Therapeutics | Maintained: Buy | n/a | $20.88 | - | 4 | Jul 7, 2026 | |
| PYXS Pyxis Oncology | Reiterated: Hold | n/a | $2.61 | - | 10 | Jun 30, 2026 | |
| LNTH Lantheus Holdings | Maintained: Buy | n/a | $105.57 | - | 15 | Jun 27, 2026 | |
| EXEL Exelixis | Reiterated: Buy | n/a | $56.74 | - | 58 | Jun 22, 2026 | |
| VKTX Viking Therapeutics | Reiterated: Buy | n/a | $40.52 | - | 37 | Jun 9, 2026 | |
| GPCR Structure Therapeutics | Reiterated: Buy | n/a | $54.67 | - | 10 | Jun 8, 2026 | |
| CRDF Cardiff Oncology | Reiterated: Buy | n/a | $1.32 | - | 17 | Jun 3, 2026 | |
| TNYA Tenaya Therapeutics | Maintained: Buy | n/a | $0.8801 | - | 4 | Jun 3, 2026 | |
| CRBP Corbus Pharmaceuticals Holdings | Maintained: Buy | n/a | $9.53 | - | 15 | Jun 1, 2026 | |
| AARD Aardvark Therapeutics | Reiterated: Buy | n/a | $4.80 | - | 5 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $3.10 | - | 10 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $4.87 | - | 8 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $7.30 | - | 27 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $0.7036 | - | 17 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $23.95 | - | 12 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $72.88 | - | 30 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $32 | $28.67 | +11.61% | 1 | Apr 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $45.29 | - | 3 | Mar 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $0.646 | - | 9 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.9609 | n/a | 15 | Dec 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $1.49 | n/a | 22 | Dec 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $133.63 | n/a | 1 | Feb 12, 2019 |
Kailera Therapeutics
Jul 7, 2026
Maintained: Buy
Price Target: n/a
Current: $20.88
Upside: -
Pyxis Oncology
Jun 30, 2026
Reiterated: Hold
Price Target: n/a
Current: $2.61
Upside: -
Lantheus Holdings
Jun 27, 2026
Maintained: Buy
Price Target: n/a
Current: $105.57
Upside: -
Exelixis
Jun 22, 2026
Reiterated: Buy
Price Target: n/a
Current: $56.74
Upside: -
Viking Therapeutics
Jun 9, 2026
Reiterated: Buy
Price Target: n/a
Current: $40.52
Upside: -
Structure Therapeutics
Jun 8, 2026
Reiterated: Buy
Price Target: n/a
Current: $54.67
Upside: -
Cardiff Oncology
Jun 3, 2026
Reiterated: Buy
Price Target: n/a
Current: $1.32
Upside: -
Tenaya Therapeutics
Jun 3, 2026
Maintained: Buy
Price Target: n/a
Current: $0.8801
Upside: -
Corbus Pharmaceuticals Holdings
Jun 1, 2026
Maintained: Buy
Price Target: n/a
Current: $9.53
Upside: -
Aardvark Therapeutics
May 15, 2026
Reiterated: Buy
Price Target: n/a
Current: $4.80
Upside: -
May 13, 2026
Reiterated: Hold
Price Target: n/a
Current: $3.10
Upside: -
May 13, 2026
Reiterated: Buy
Price Target: n/a
Current: $4.87
Upside: -
May 12, 2026
Reiterated: Hold
Price Target: n/a
Current: $7.30
Upside: -
May 12, 2026
Reiterated: Buy
Price Target: n/a
Current: $0.7036
Upside: -
May 11, 2026
Reiterated: Hold
Price Target: n/a
Current: $23.95
Upside: -
May 7, 2026
Reiterated: Buy
Price Target: n/a
Current: $72.88
Upside: -
Apr 29, 2026
Initiated Coverage: Buy
Price Target: $32
Current: $28.67
Upside: +11.61%
Mar 6, 2026
Downgraded: Hold
Price Target: n/a
Current: $45.29
Upside: -
Aug 7, 2025
Reiterated: Buy
Price Target: n/a
Current: $0.646
Upside: -
Dec 22, 2023
Rated: Hold
Price Target: n/a
Current: $0.9609
Upside: n/a
Dec 1, 2021
Downgraded: Hold
Price Target: n/a
Current: $1.49
Upside: n/a
Feb 12, 2019
Maintained: Buy
Price Target: n/a
Current: $133.63
Upside: n/a